Poster Abstracts • OFID 2018:5 (Suppl 1) • S129 adjacent disc that were similar to those seen in bacterial discitis. As early as 2001 Stirling noted a relationship between sciatica and Propionibacterium acnes cultured from disc space material obtained at discectomy. In 2013 Albert demonstrated that Modic type I changes, strongly associated with low back pain, responded to 100 days of antibiotic treatment in a large randomized controlled trial. The findings were controversial, and we proposed that modern microdiscectomy techniques would minimize the potential for contamination with the common skin bacteria reported most often in previous studies.
Background. The Infectious Diseases Society of America (IDSA) guidelines observed that prescribing CAS for treatment of PJI is an unresolved issue. We aimed to characterize variation in the use of CAS while accounting for patient-level factors to identify targets for antimicrobial stewardship in the Veterans Affairs system. Methods. A retrospective cohort study was conducted using data on veterans with a diagnosis of S. aureus PJI between 2003 and 2015. Patients managed with debridement, one-stage exchange (OSE), or two-stage exchange (TSE) were included. Differences in characteristics between any CAS and no CAS treatment (None) were determined by the Mann-Whitney U test for continuous variables and Fisher's exact test for dichotomous variables. Generalized linear-mixed models were used to calculate the risk standardized measure (observed to expected [O/E] ratio) of a hospital's CAS use.
Results. Nine hundred forty-four (75%), 310 (25%), and 11 (<1%) were managed with debridement, TSE, and OSE, respectively, among the 1,265 included patients. CAS was prescribed in 80% of debridement patients, 49% of TSE patients, and 100% of OSE patients. Patient factors associated with CAS use were different for debridement and TSE (table) . Risk adjusted models demonstrated greater variability among facilities using CAS after TSE compared with debridement and the overall cohort (figure).
Conclusion. There is substantial variation in the use of CAS by patient characteristics for S. aureus PJI across the VHA system. This variation differs between debridement and TSE surgery patients. Further research is warranted to guide CAS recommendations. Background. Optimal antibiotic therapy following surgery for prosthetic joint infection (PJI) depends on potency, toxicity, convenience, and cost. Daptomycin, a potent, convenient, and low-toxicity antibiotic, is FDA approved for the treatment of skin and soft-tissue infections, but its role in treatment of PJI is less clear. We reviewed our experience with daptomycin in the treatment of staphylococcal PJI.
Methods. A retrospective cohort of staphylococcal hip and knee PJI treated with daptomycin after debridement (I&D) or two-stage exchange was identified by query of hospital coding records from 2009 to 2014, with subsequent chart review. All cases met Musculoskeletal Infection Society International Consensus criteria for PJI; all staphylococcal species were included. The primary endpoint was defined in debrided joints as retention of the prosthesis at 2-year follow-up, and for two-stage exchanges, as prosthesis retention for 2 years from reimplantation. Descriptive statistics were completed using the Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables.
Results. Two hundred forty-one patients with staphylococcal PJI were identified: 148 two-stages (112 [75%] had success at 2 years) and 95 I&Ds (44 [47%] had success at 2 years. Twenty-eight (19%) two-stages and nine (10%) of debridements received daptomycin; of which, 20 two-stages (72%) and six debridements (66%) reached a successful 2-year outcome. In univariate analysis, there was no association between success and receipt of daptomycin in patients with staphylococcal PJI (two-stages, P = 0.71; debridement, P = 0.63). There were no associations noted between outcome and age, sex, or BMI.
Conclusion. Daptomycin appeared no better or worse than comparator antibiotics in a relatively large retrospective cohort of staphylococcal hip and knee PJI patients, regardless of surgical strategy. Given its favorable convenience and toxicity profile, it is an attractive antibiotic choice for staphylococcal PJI despite its high cost.
Disclosures. All authors: No reported disclosures. Background. Two-stage exchange is the standard treatment of periprosthetic joint infection in the United States. Occasionally, for selected patients, temporary antibiotic-loaded spacers are retained "permanently" instead of proceeding with prosthesis re-implantation. It is unclear whether the "retained" spacer represents a nidus for re-infection, and would require secondary antibiotic suppression to prevent recurrence of infection. We aim to determine the risk of re-infection among patients with retained knee and hip spacers, and assess the role of antibiotic suppression.
Joint Spacer Retention, Antimicrobial Suppression, and Risk of Re-infection
Methods. We identified 51 patients with retained static or articulating knee (n = 34) and hip (n = 17) spacers between 1996 and 2014 using the Mayo Clinic Hospital Orthopedic database. Medical records were reviewed to collect clinical data, including antibiotic use and offending organisms. We compared the cumulative incidence of reinfection between those with or without suppression using a competing risk model, with death and revision for mechanical failure as competing risks.
Results. The median age was 77 years (range, 48-94). Gender distribution was equal. The median Charlton Comorbidity Index (CCI) was 3 (1-11), while median BMI was 30.1 (17.8-59.5). Eleven of 51 patients received antibiotic suppression after spacer retention. A history of prior antibiotic suppressive therapy was the only variable associated with being placed back on antibiotic suppression after spacer retention [OR 18 (95% CI 3.2-100)]. During the median follow-up period of 31.3 months, there were five re-infections. The cumulative incidence of re-infection was not significantly different between suppressed and unsuppressed groups (P = 0.89). The re-infecting pathogens were different from the index offending organisms. Only the presence of preoperative draining sinus was significantly associated with re-infection [OR 10 (95% CI 1-99.6)].
Conclusion. In selected patients where a second-stage prosthesis re-implantation is not an option, and retention of "temporary" antibiotic loaded spacer is surgically preferred, the risk of re-infection was not prevented by prolonged antibiotic suppression. The presence of a draining sinus was significantly associated with re-infection, often with new pathogens.
Disclosures. All authors: No reported disclosures. Background. Parechovirus (PeV), specifically Parechovirus A type 3 (PeV-A3), is a picornavirus associated with severe infection in young infants, with disease manifestations ranging from undifferentiated fever, to sepsis like illness, and meningoencephalitis. There are limited data regarding long-term outcomes of infected infants. The objective of this study was to describe early childhood outcomes following infantile PeV-CNS infection Methods. Families of Infants hospitalized during 2014 with laboratory confirmed PeV-CNS infection were contacted for neurodevelopmental follow-up. Testing included medical history, standard neurologic examination, parental completion of Ages and Stages questionnaire (ASQ) and determination of Bayley III cognitive, motor, and language quotients. Neurodevelopmental impairment (NDI) was considered present if cognitive, motor, or language quotients were >1 standard deviation (mild) or >2 SD (severe) below the testing norms, the presence of cerebral palsy (CP), or sensory (vision/hearing) impairment. Relationship of childrens' outcomes to severity of PeV disease (uncomplicated febrile illness [mild], disseminated disease [moderate] or advanced disease requiring intensive care [severe]) was assessed by chi-square analysis.
Childhood Outcomes Following Parechovirus Central Nervous System Infection in Young Infants at a US Children's Hospital
Results. Nineteen children were available for testing at approximately 3 years of age (31-38 months), 12 (63%) with mild, five (26%) moderate, and two (11%) with severe disease. Mean Bayley quotients were within normal limits (see table) , one infant had mild CP (5%) and two (11%) had mild NDI. There was no apparent relationship of NDI with infant PeV clinical presentation. ASQ results included 11% at referral level and 32% suspect, and were unrelated to severity of the viral illness. However, all parents of children with moderate or severe presentations of infantile PeV disease had medical or behavior concerns at 3 years of age compared with 25% of those with mild presentation (P = 0.007). Conclusion. Neurodevelopmental impairments may be seen following infant PeV disease, but may not correlate with severity of clinical disease. Longitudinal monitoring of developmental status through early childhood following PeV infantile disease is warranted.
Disclosures. All authors: No reported disclosures. Background. ICD-9 codes have been widely used in studies utilizing large national databases that evaluate the clinical epidemiology of encephalitis in the United States. Many studies have showed that ICD-9 codes have poor accuracy in stroke, multiple sclerosis and pulmonary fibrosis but their utility in encephalitis is unknown.
Lack of Accuracy of the
Methods. Retrospective study of all adults with a discharge diagnosis of encephalitis by an ICD-9 code. The study was performed in 17 hospitals from the Memorial Hermann Hospital and Harris Health Hospital system in the Greater Houston area from March 2010 until July 2015. Medical records were reviewed and a case was considered accurately classified as encephalitis if they met the definition established by the international encephalitis consortium.
Results. A total of 1,241 cases were identified by a discharge diagnosis of ICD-9 code as having encephalitis. The most common cause identified was not having a central nervous system infection in 580 (46.7%) patients. A total of 244 (19.6%) patients were correctly identified as having encephalitis. Other causes identified were nosocomial meningitis (11.9%), community-acquired bacterial meningitis (8.1%), aseptic meningitis (5.8%), fungal meningitis (5.4%), tuberculosis (2.0%), and parasitic meningitis (0.2%).
Conclusion. ICD-9 codes have poor reliability in identifying patients with encephalitis questioning the accuracy of large nationwide studies that utilize them to identify patients. Background. Neurosyphilis (NS) is an infection of the central nervous system caused by Treponema pallidum. Intramuscular (IM) penicillin (PCN) G procaine is a treatment option for those who cannot receive or decline intravenous (IV) therapy. Since August 24, 2016, it has been unavailable from the manufacturer, necessitating the use of IV PCN for NS. Our institutions organized a multidisciplinary, coordinated care system to expedite outpatient treatment of NS upon diagnosis. We report successful management of NS at an urban safety-net hospital in the post-procaine PCN era.
Methods. We identified patients with suspected NS from the King County Public Health STD and Harborview Infectious Disease clinics from October 2016 to February 2018. Demographics, clinical symptoms, diagnostics, treatment, and outcomes were collected by chart review. Successful NS treatment was defined as resolution of cerebrospinal fluid (CSF) pleocytosis or elevated protein, improvement in neurologic symptoms or appropriate decrease in serum rapid plasma reagin (RPR) or CSF Venereal Disease Research Laboratory (VDRL) titers. 
